Laurent Pharmaceuticals Provides Clinical Development Update

8 April 2021

Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 PatientsCompletes...

Read More

Laurent Pharmaceuticals Receives Approval from FDA to initiate its COVID-19 Phase 2 Clinical Trial in the United States

27 August 2020

The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against...

Read More


Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021